Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00540553 · ClinicalTrials.gov registry record · Phase 1
Study to Test Safety, Tolerability and Blood Levels of GSK971086 After 1 Dose & 7 Days of Dosing in Healthy Adult Males
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 126
- Enrollment target
NCT00540553 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 126 participants.
The verdict
NCT00540553, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 126 participants
- Enrollment target
Study Summary
This research study is the first administration of GSK971086 in humans. The purpose of this study is to assess the safety and tolerability of GSK971086, as well as, how much GSK971086 is in your blood after different doses
Interventions
- DRUG placebo
- DRUG GSK971086
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 126 participants |
| Start Date | 2007-08 |
| Est. Completion | 2008-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00540553
The ClinicalTrials.gov registry entry for NCT00540553 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 126 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00540553 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00540553 about?
NCT00540553 is a clinical study titled "Study to Test Safety, Tolerability and Blood Levels of GSK971086 After 1 Dose & 7 Days of Dosing in Healthy Adult Males". This research study is the first administration of GSK971086 in humans. The purpose of this study is to assess the safety and tolerability of GSK971086, as well as, how much GSK971086 is in your blood after different doses
What is the current status of trial NCT00540553?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 126 participants. The study started on 2007-08. Estimated completion is 2008-04.
What interventions are being tested in trial NCT00540553?
The interventions under investigation include: placebo (DRUG), GSK971086 (DRUG).
Who is sponsoring clinical trial NCT00540553?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.